Tempus AI (TEM) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Tempus AI published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Tempus AI reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Beginning in 2026, Tempus reports xG (hereditary testing sold to oncologists) within Hereditary, and applied the change to 2025 volumes and revenue.
• Tempus reports in thousands; figures here are in millions. Its pending acquisition of Personalis cleared regulatory review, with the Personalis shareholder vote planned for November 30, 2026.

Source: Tempus AI Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Tempus AI splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Tempus AI's Diagnostics revenue was $303 million in Q3 2026, up 20% from $253 million in Q3 2025, 74% of total revenue.
• Tempus AI's Data and applications revenue was $108 million in Q3 2026, up 33% from $81.3 million in Q3 2025, 26% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Tempus AI said:

“Tempus is increasing its full year 2026 revenue guidance to $1.60 to $1.605 billion, which represents ~25% annual growth.”

“We continue to expect 2026 Adjusted EBITDA to be ~$65 million.”

Source: Tempus Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the TEM forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total net revenue and GAAP diluted net income (loss) per share, each as first reported in that quarter's release. Q2 2026 was Tempus's one quarter of GAAP net income in this run, $5.6 million.

We do not hold a confirmed date for Tempus AI's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Tempus AI reports revenue in two product lines. In Q3 2026 Diagnostics brought in $303.5 million, up 20%, and Data and applications $108.1 million, up 33%, for total revenue of $411.5 million, up 23%. Diagnostics combines Oncology testing (legacy Tempus) and Hereditary testing (legacy Ambry Genetics). (Tempus AI Q3 2026 release, Nov 2, 2026; Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026)

Tempus ran approximately 244,500 tests in the quarter against approximately 217,000 a year earlier. Oncology tests rose from approximately 77,000 to approximately 101,500, adding $38.1 million of Oncology revenue, while Hereditary tests rose from approximately 140,000 to approximately 143,000, adding $3.7 million. Minimal Residual Disease (MRD) volume was about 12,000 tests, up 300%. (Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026; Tempus AI Q3 2026 release, Nov 2, 2026)

Tempus's Data and applications line licenses de-identified data generated through its Diagnostics business to pharmaceutical and biotechnology companies for drug development, along with AI-enabled clinical trial matching and analytical services. Tempus says this revenue is typically back-weighted towards the second half of the year because of customers' budgeting cycles. In Q3 2026 the line grew by $19.9 million from its Insights products and $6.4 million from Next. (Tempus AI Form 10-K, 2025, Feb 24, 2026; Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026)

Some of that data revenue comes from related parties: Data and applications included $22.1 million of revenue from Pathos AI in Q3 2026, against $24.9 million a year earlier. Tempus's remaining performance obligations on multi-year contracts were $514.0 million at September 30, 2026, and its total data licensing bookings passed $550 million for the year to date after an October collaboration with BMS worth up to $137.5 million over five years. (Tempus AI Q3 2026 release, Nov 2, 2026; Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026)

Tempus AI's GAAP net loss was $14.9 million, or $(0.08) per share, in Q3 2026, against $80.0 million, or $(0.46), a year earlier. Its non-GAAP net income was $13.4 million, or $0.07 per share. The GAAP loss included $50.8 million of stock-based compensation and related employer payroll taxes and $42.8 million of unrealized gains on marketable securities. (Tempus AI Q3 2026 release, Nov 2, 2026)

Tempus's non-GAAP net income excludes fair value changes on marketable equity securities and holdback liabilities (a $41.5 million gain this quarter), stock-based compensation of $48.1 million, amortization of acquired intangibles of $16.7 million, acquisition-related expenses of $3.7 million and equity-method losses. Other income, net was $47.1 million against $2.6 million a year earlier, because Tempus marks its Recursion and Personalis shares to market each quarter. Interest expense fell to $6.7 million from $15.4 million. (Tempus AI Q3 2026 release, Nov 2, 2026; Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026)

Tempus's weighted-average share count was 181,311 thousand in Q3 2026, against 174,945 thousand a year earlier, and basic and diluted figures are the same because of the net loss. Tempus keeps a full valuation allowance on its U.S. federal and state deferred tax assets, so its tax provision was $35 thousand. Adjusted EBITDA was $25.6 million, against $1.5 million in Q3 2025. (Tempus AI Q3 2026 release, Nov 2, 2026; Tempus AI Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Tempus AI gives a full-year outlook in its release. With Q3 2026 it raised full-year 2026 revenue guidance to $1.60 to $1.605 billion, about 25% growth, and kept its expectation of about $65 million of Adjusted EBITDA. Revenue for the first nine months was $1,142.1 million and Adjusted EBITDA was $30.8 million. (Tempus AI Q3 2026 release, Nov 2, 2026)

Tempus does not give guidance for net loss, the GAAP measure closest to Adjusted EBITDA. The pending Personalis acquisition has cleared regulatory review, and the Personalis shareholder meeting to approve it is planned for November 30, 2026. (Tempus AI Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover Tempus AI, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Tempus AI's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TEM is on is TEM a buy or a sell?, what analysts expect next is on the TEM forecast, and what the company does is on the Tempus AI (TEM) stock page.

Every number on this page can be traced to a document Tempus AI published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.